These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22825518)

  • 21. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
    QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
    Faivre S; Niccoli P; Castellano D; Valle JW; Hammel P; Raoul JL; Vinik A; Van Cutsem E; Bang YJ; Lee SH; Borbath I; Lombard-Bohas C; Metrakos P; Smith D; Chen JS; Ruszniewski P; Seitz JF; Patyna S; Lu DR; Ishak KJ; Raymond E
    Ann Oncol; 2017 Feb; 28(2):339-343. PubMed ID: 27836885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
    Dos Santos C; Tijeras-Raballand A; Serova M; Sebbagh S; Slimane K; Faivre S; de Gramont A; Raymond E
    Br J Cancer; 2015 Jan; 112(1):86-94. PubMed ID: 25422908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
    Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
    J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.
    Patel PH; Senico PL; Curiel RE; Motzer RJ
    Clin Genitourin Cancer; 2009 Jan; 7(1):24-7. PubMed ID: 19213664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
    Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
    Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
    Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
    J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent studies show promise for treating rare pancreatic tumors.
    Peres J
    J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in pancreatic neuroendocrine tumor treatment.
    van der Veldt AA; Kleijn SA
    N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
    [No Abstract]   [Full Text] [Related]  

  • 33. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
    Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
    BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
    Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
    Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
    Lin LZ; Li P; Chen HR; Pang LJ
    Future Oncol; 2013 Jun; 9(6):909-13. PubMed ID: 23718311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
    Blumenthal GM; Cortazar P; Zhang JJ; Tang S; Sridhara R; Murgo A; Justice R; Pazdur R
    Oncologist; 2012; 17(8):1108-13. PubMed ID: 22836448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
    Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
    Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.